Detalles de la búsqueda
1.
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
BMC Cancer;
22(1): 752, 2022 Jul 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35820889
2.
Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations.
Bioorg Med Chem Lett;
66: 128730, 2022 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35421578
3.
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Nat Chem Biol;
13(4): 381-388, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28135235
4.
Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
Clin Cancer Res;
29(1): 183-196, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36240005
5.
FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia.
Transl Oncol;
15(1): 101244, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34710737
6.
Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both.
Oncogene;
41(12): 1691-1700, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35102249
7.
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.
Clin Cancer Res;
28(24): 5455-5468, 2022 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36048524
8.
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.
J Med Chem;
65(7): 5317-5333, 2022 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35352560
9.
MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models.
Cell Death Discov;
7(1): 90, 2021 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33941774
10.
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
J Immunother Cancer;
7(1): 327, 2019 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31779710
11.
Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.
Cell Biosci;
9: 88, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31673329
12.
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
J Med Chem;
60(6): 2215-2226, 2017 03 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28092155
13.
Oncogenic dependency on ß-catenin in liver cancer cell lines correlates with pathway activation.
Oncotarget;
8(70): 114526-114539, 2017 Dec 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-29383099
14.
Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.
Oncotarget;
7(5): 5461-9, 2016 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26701727
15.
Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development.
Oncotarget;
6(24): 20160-76, 2015 Aug 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-26062443
16.
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
J Thorac Oncol;
9(3): 285-94, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24496003
17.
Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Stem Cells Transl Med;
2(3): 233-42, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23408105
18.
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.
Front Med;
7(4): 462-76, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23820871
19.
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
PLoS One;
8(6): e67258, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23826249
20.
Identification of cancer stem cells provides novel tumor models for drug discovery.
Front Med;
6(2): 112-21, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22573222
Resultados
1 -
20
de 20
1
Próxima >
>>